Reported quarterly revenue of $8.1 million, a 41% year-over-year increase; Accelerated growth of SmartFrame OR ™ platform and ClearPoint Prism ® Laser Therapy System, contributing to record navigation ...

The quest for enhanced cognitive function has never been more crucial in a world bustling with information overload and ...

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system. Microglia, the primary immune cells of the central ...

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively. Check out my recommendation for CLPT ...

Finding the right remedy can feel daunting in a world increasingly dominated by stress and sleepless nights. Sleep is a vital component of our overall health, affecting everything from mood and ...

Informed by conversations in 2023 around challenges and opportunities in research and therapeutic development for rare neurological diseases, the Rare Neurological Diseases Action Collaborative was ...

Anavex (AVXL) presented new data from the Phase IIb/III study showing that blarcamesine, once daily orally, demonstrates pre-specified clinical ...

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

Data of Blarcamesine confirm upstream SIGMAR1 activationPresented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...

Sobi® (STO: SOBI) today announced that new research showing the effect of emapalumab in patients with macrophage activation syndrome (MAS) ...